Company Overview and News
Legacy Reserves (LGCY), an upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP gainer in the week ending April 13, 2018. Legacy Reserves rallied 17.4% last week. The rally was mainly due to strong gains in crude oil prices.
So far in this series, we have discussed the performance of the broader MLP sector, the top MLP gainers, and the top MLP losers in the week ending April 13, 2018. In this part, we’ll discuss the MLP rating updates last week.
President Donald Trump told reporters last week that his administration might remove the restrictions that prevent E15 blends from being made available year-round.
Sanchez Midstream Partners (SNMP) is a midstream MLP involved mainly in natural gathering, processing, and compression. Sanchez Midstream Partners was the top MLP gainer in the week ending April 6, 2018. Sanchez Midstream Partners rallied 16.4%. The company’s YTD (year-to-date) return turned positive due to last week’s gain. Sanchez Midstream Partners has risen 8.6% YTD. Despite the recent gains, Sanchez Midstream Partners has still fallen ~21% in the past year.
Short interest as a percentage of float in CVRR Refining (CVRR) is 2.23%, compared with 2.22% in mid-March 2018. According to data released on March 26, 2018, CVRR Refining’s total shares shorted stood at ~1.12 million on March 15, 2018, 0.6% higher than its ~1.11 million shares shorted on February 28, 2018. CVRR Refining’s short interest is lower than its average of ~2.8% over the last five years.
CVR Energy (CVI) owns 65.9% of CVR Refining’s (CVRR) outstanding shares. Icahn Associates, Goldman Sachs, and Acadian Asset Management are the three largest institutional investors in CVR Refining, with 3.9%, 2.0%, and 1.1%, respectively, of CVRR’s outstanding shares. The top nine investors, excluding CVR Energy, collectively own ~11% of CVR Refining’s outstanding shares.
CVR Refining (CVRR) stock has fallen 13% so far in 2018. In comparison, Calumet Specialty Products Partners (CLMT) has fallen 8%, the Alerian MLP ETF (AMLP) has fallen 12%, and crude oil prices have risen ~5%. In this series, we’ll look at CVR Refining’s recent performance and analyze its key indicators.
In this part of our series, we’ll look at the top-percentage gainers from the US refining and marketing sector this week. To compile the list of top refining and marketing gainers, we’ve selected refining and marketing companies with market capitalizations greater than $100 million and average trading volume greater than 100,000 shares last week.
The share price of refiner Andeavor jumped to a 2-month high following news that some of its refineries have been granted "hardship exemptions" from the national biofuels mandate.
Midstream firms, Dominion, Sanchez, & Energy Transfer topped February's broker-vetted Energy Sector gains list, while Awilco Drilling, was tops by yield, as calculated 3/28/18.
How energy investors can be too far-sighted in quantifying the impacts of new trends, the outlook for the biofuels market, and the impact of climate change are topics discussed.
Legacy Reserves (LGCY), the upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) exploration and production, was the top MLP gainer in the week ending March 23. Legacy Reserves rose 11.8% last week. The company’s strong gains last week could be attributed to a sharp increase in crude oil prices. Overall, Legacy Reserves has risen 177.6% since the beginning of 2018. Read Legacy Reserves Has Risen Over 140% in 2018: Can It Rise Further? to learn more.
MLP investors have certainly seen their conviction tested of late. Poor stock performance was recently compounded by the Federal Energy Regulatory Commission’s (FERC) ruling on cost of service contracts earlier this month. Although MLPs don’t pay tax, interstate natural gas pipeline tariffs based on cost-of-service have historically included an allowance for taxes paid by their investors. Following a court challenge by United Airlines, FERC has now disallowed this practice.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET